Free Trial
NASDAQ:SRZN

Surrozen Q4 2023 Earnings Report

Surrozen logo
$8.14 +0.83 (+11.35%)
Closing price 05/22/2025 03:59 PM Eastern
Extended Trading
$8.14 -0.01 (-0.06%)
As of 05/22/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surrozen EPS Results

Actual EPS
-$4.24
Consensus EPS
-$4.25
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Surrozen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Surrozen Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Surrozen's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Surrozen Earnings Headlines

Research Analysts Set Expectations for Surrozen Q2 Earnings
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Surrozen's (SRZN) Buy Rating Reaffirmed at HC Wainwright
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN), a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

View Surrozen Profile

More Earnings Resources from MarketBeat